Testing

David Murray, M.D., Ph.D., provides a brief overview of the new Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum test now available from Mayo Medical Laboratories. This test should be ordered for individuals suspected of A1A deficiency and can be used for diagnosis and identification of a specific proteotype to determine prognosis.

By Andy Tofilon • December 19, 2013

Mayo Clinic studies, involving thousands of patients, have found the new cell-based AQP4 antibody assay to be more sensitive and specific than ELISA methods.

By brentwestra • December 17, 2013

Robin Patel, M.D., chair of Mayo Clinic’s Division of Microbiology, provides a three-minute overview of a new test for Coxiella burnetii, the causative agent of Q fever. The real-time PCR test rapidly detects Coxiella burnetii DNA in clinical specimens by targeting a sequence of the shikimate dehydrogenase gene (aroE) unique to Coxiella burnetii.

By Andy Tofilon • November 13, 2013

Starting this week, a select number of Mayo Medical Laboratories test results will include a supplemental report, providing more details and/or improved format than what is currently possible with our laboratory information system. This new functionality, to be available for 13 tests initially, will enable you to view an additional report, which may include more information, charts, images and other enriched information.

By Andy Tofilon • November 4, 2013

Melanocytic tumors arising in the skin can present a significant diagnostic challenge. While many lesions can be easily classified as benign nevi or malignant melanoma based on histologic features alone, there is a significant subset of lesions that cannot be clearly defined as either benign or malignant. To aid in diagnosis and differentiation of malignant from benign melanocytic lesions, a (FISH)-based test panel has been developed.

By Andy Tofilon • September 26, 2013

To create more efficient ordering and send out processes for our clients, Mayo Medical Laboratories is pleased to introduce our Universal Pathology Consultation, which will be available on Aug. 19. Based on client feedback, Mayo Medical Laboratories has reengineered its accessioning and laboratory path-of-workflow to enable our clients to obsolete existing codes and now order any specialty of pathology consultation using a streamlined ordering process.

By brentwestra • August 5, 2013

These disorders are commonly mistaken for multiple sclerosis, stroke, and untreatable degenerative disorders.

By brentwestra • August 1, 2013

In the United States, major tick-borne diseases include Lyme disease, anaplasmosis, babesiosis, ehrlichiosis, and Rocky Mountain spotted fever. Historically, only certain pockets of the United States posed a risk for tick-borne disease. However, the geographic range of ticks has expanded and large areas of the population are now at risk. Because of this increased risk, it is important that physicians recognize who to test, when to test, and what test to use.

By mayocliniclabs • June 24, 2013

Full content can be viewed here.

By brentwestra • May 30, 2013

Mayo Clinic and Cancer Genetics Inc. today launched OncoSpire Genomics, a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing. OncoSpire will focus on mutually identified projects in the Biomarker Discovery Program within Mayo’s Center for Individualized Medicine. Mayo Medical Laboratories and Mayo Clinic’s Department of Laboratory Medicine and Pathology will work with Mayo’s Center for Individualized Medicine to help bring discoveries from the joint venture to patients at Mayo Clinic and elsewhere.

By mayocliniclabs • May 22, 2013

Mayo Medical Laboratories is now performing NMR lipoprotein particle testing using the LipoScience, Inc. Vantera® Analyzer, which identifies and quantifies concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. Read more for full details and test information.

By mayocliniclabs • May 22, 2013

Pyrazinamide is one of the four first-line agents used to treat Mycobacterium tuberculosisinfections. It is a unique agent in regards to susceptibility testing because it requires testing under acidic conditions, and it is well documented in relevant literature that current broth methods tend to overcall resistance to this agent.

By mayocliniclabs • May 20, 2013

Mycobacteria are a genera of bacteria with a unique cell wall structure which makes them resistant to drying, disinfectants, UV light, and many antibacterial agents. There are approximately 160 species of mycobacteria, some of which have extremely slow growth rates (12 to 24 hour generation time), therefore they may require up to six weeks for growth in a culture.

By mayocliniclabs • May 16, 2013